Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 189 results for "Byetta"

Human medicines European public assessment report (EPAR): By...

This is a summary of the European public assessment report (EPAR) for Byetta. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and ... European Medicines Agency, 5 days ago
GLP-1 Receptor Agonists in T2DM -- Guidelines vs Practice General Medicine eJournal, 2 months ago

1 images for "Byetta"

PRWeb, 2 days ago
PRWeb

Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases

Hundreds of Byetta lawsuits (http://www.byettalawsuit.com) and other incretin mimetic claims continue to move forward in U.S. courts, Bernstein Liebhard LLP reports. According to a statement issued by AstraZeneca PLC on July 31, 2014, Byetta and ...
 Digital Journal2 days ago Byetta Lawsuit News: Bernstein Liebhard LLP Notes British Columbia's Recent Decision to Discontinue Incretin Mimetic Drug Coverage from PharmaCare Program  Digital Journal2 weeks ago Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Establishes Deadlines Pertaining to Discovery, Bernstein Liebhard LLP Reports  Digital Journal1 month ago
[x]  
PRWeb

Byetta Lawsuit News: New Order Establishes Deposition Protocol For Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Reports

Byetta lawsuits (http://www.byettalawsuit.com) and legal claims involving other incretin mimetic Type 2 diabetes drugs, such as Januvia and Victoza, continue to move forward in a federal multidistrict litigation now underway in U.S. District Court, ...
 Digital Journal3 weeks ago
[x]  
Xconomy

BioKier Takes a Shot at a New Kind of Diabetes Drug

Diabetics know all too well that needle sticks are a routine part of managing their disease. Insulin injections have been part of the diabetes standard of care for decades. And in recent years, a new class of injectable drugs have emerged to help ...
 Xconomy1 week ago Will A Single Injection Help Stop Diabetes In Its Tracks?  Times of India1 month ago Treatment reverses symptoms of type 2 diabetes in mice, without side effects  Medical News Today1 month ago Injection Reverses Type 2 Diabetes in Mice  Nutrition Review1 month ago
[x]  
Jutia Group

Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) U.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy

[Business Wire] Bristol-Myers Squibb Company and Pfizer Inc. today announced the U.S. Food and Drug Administration has approved a Supplemental New Drug Application for Eliquis for the treatment of DVT and PE, and for the reduction in the risk of ...
 Jutia Group1 week ago Stock Update (NYSE:BMY): Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis® (apixaban) at the ESC Congress 2014  Jutia Group1 week ago Bristol-Myers Squibb Company (NYSE:BMY) | Leica Biosystems and Bristol-Myers Squibb Enter Into a Development and Commercialization Collaboration for Companion Diagnostics that Support Targeted Therapies  Jutia Group3 weeks ago Second Quarter & Half Year Results 2014  TrustNet1 month ago

GBK Presents a Luxury Gift Lounge Honoring the Nominees and Presenters of the 2014 Emmy® Awards - August 22nd and 23rd - Beverly Hills

(Date:8/19/2014)... The elegant bamboo floorings from BambooIndustry.com ... houses in an environmentally conscious way with the company's ... and have an aluminum oxide finish to help resist ... high-traffic areas. , Recently, the company has ...
 Bio-Medicine1 week ago

Lawsuit Settlement News Website Reports Update on Risperdal Litigation Due to Increase of Filed Cases

PHILADELPHIA, Aug. 15, 2014 /PRNewswire/ -- MT Services LLC, A Lawsuit Settlement News Reporting Company, which operates a lawsuit help center: lawsuitsettlementnews.com, announced today that there is ongoing litigation for victims of the ...
 TickerTech.com2 weeks ago Lawsuit Settlement News Reports Bad Pharmaceutical Drug Cases Are Ongoing While Funding For Cash Advances and Free Attorney Legal Consultations Are Available  RCL Advisors1 month ago
[x]  

Biotech Stock Directory Update

(Investorideas.com Newswire) Investorideas.com staff: Investorideas.com, a global news source covering leading sectors issues the updated biotech stock directory for August. The directory is part of the member's directory list including tech and ...
 InvestorIdeas.com2 weeks ago
Scottrade

Aegis Therapeutics, LLC Release: First Non-Injectable GLP-1 Analog For Type-2 Diabetes

) - Aegis announced today that it is offering an exclusive license to develop, commercialize, and sell its patented non-invasive exenatide metered nasal spray diabetes drug. Exenatide is a 39-amino acid synthetic peptide GLP-1 analog highly ...
 BioSpace3 weeks ago First Non-Injectable GLP-1 Analog for Type-2 Diabetes  4 Traders3 weeks ago
[x]  
Pharma Letter

AstraZeneca (AZN) Beats on Q2 Earnings, Guidance Raised

AstraZeneca ( AZN ) reported second-quarter 2014 core earnings of $1.30 per American Depositary Share ( ADS ) beating the Zacks Consensus Estimate of $1.13. Earnings were also up 13% (at constant exchange rates or CER) year over year buoyed by ...
 Yahoo! Finance1 month ago AstraZeneca 2nd-qtr earnings leap, beating expectations  Pharma Letter1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less